- Lexaria Bioscience is a global innovator in drug delivery platforms, developing a technology designed to improve the performance of other medicinal products by making them more rapidly and effectively usable by patients’ bodies
- Lexaria’s patented DehydraTECH technology has been studied in combination with a number of other products, including but not limited to, cannabidiol (“CBD”), oral nicotine, antivirals, NSAIDs, and erectile dysfunction therapies
- The company is pursuing FDA approval under the Investigational New Drug (“IND”) process to clinically test its DehydraTECH-CBD for the treatment of high blood pressure
- A driving focus of the company’s R&D has been to improve the speed of onset, increase bioavailability and brain absorption of active pharmaceutical ingredients
A common refrain in the world of advertising medicinal substances is that a select product can enhance a patient’s ability to live an active life despite debilitating medical conditions.
“By helping to control eczema with Dupixent you can show more (skin),” one prominent ad message declared in recent months, while another offered examples of hope by testifying, “Opdivo plus Yervoy equals a chance for more starry nights” (https://cnw.fm/yBxCG).
Drug delivery innovator Lexaria Bioscience (NASDAQ: LEXX) has found a market niche in the potential of enhancing medicines’ ability to do what they do. The company’s patented DehydraTECH(TM) technology has been tested in combination with a variety of active pharmaceutical ingredients (“APIs”), processing the drug substances through a proprietary dehydration process for rapid-absorption delivery.
“Lexaria has repeatedly demonstrated that DehydraTECH-processed cannabidiol (‘CBD’) has superior delivery characteristics into the bloodstream and brain compared to generic CBD and expects to generate similar results with THC,” the company stated in regard to one set of substances last year (https://cnw.fm/jiX9J).
Lexaria is pursuing U.S. Food and Drug Administration (“FDA”) approval to begin formal, registered clinical testing for using DehydraTECH-CBD to treat hypertension following a series of successful studies.
“Lexaria has repeatedly demonstrated that DehydraTECH-processed nicotine has superior delivery characteristics compared to generic nicotine when dosed orally and swallowed for intestinal delivery to the bloodstream,” the company added in regard to another progressing area of R&D.
“Phosphodiesterase-5 inhibitor (PDE5) drugs work using a process of vasodilation, and most are considered to be slow-acting, requiring 1-2 hours to reach peak levels in the bloodstream for maximum effectiveness,” Lexaria stated in regard to still other products treating erectile dysfunction (“ED”). “Lexaria has repeatedly evidenced a greatly reduced delivery time of another drug that encourages vasodilation – DehydraTECH CBD – and theorizes whether DehydraTECH might likewise deliver PDE5 drugs more quickly and effectively. … DehydraTECH for PDE5 drugs is patent pending.”
The Company recently announced its 25th patent has been awarded for for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs — its first patent to build on studies processing antivirals such as remdesivir and ebastine with DehydraTECH to fight the COVID-19/SARS-CoV-2 virus and other biosystem invaders (https://cnw.fm/Re39u).
Lexaria will commence its human oral nicotine study NIC-H22-1 this summer. The Company is optimistic that this larger human study will produce positive findings pursuant to those evidenced in its previous 2021 subjective human testing that utilized DehydraTECH-nicotine formulations demonstrating onset of initial nicotine effectiveness in as little as 1.5 to 4 minutes after an oral dose. As the body of data regarding DehydraTECH has grown, its use in improving outcomes for a variety of conditions has generated widespread corporate optimism.
“If we can sustain these results, we could be looking at mega-drug status ($1 billion per year) in the hypertension market,” CEO Chris Bunka stated last year in regard to the DehydraTECH-CBD studies (https://cnw.fm/WRGRV). “Our goal now is to put together a 4-week study, three doses per day, targeting a sustained drop in blood pressure. That could make us one of the most effective registered pharmaceutical treatments for hypertension in the world, with few if any unwanted side effects.”
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
